Premium
Biomarker and cytologic abnormalities in women at high and low risk for breast cancer
Author(s) -
Fabian Carol J.,
Zalles Carola,
Kamel Sahar,
McKittrick Richard,
Moore William P.,
Zeiger Sandy,
Simon Connie,
Kimler Bruce,
Cramer Ann,
Garcia Fernando,
Jewell William
Publication year - 1993
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.240531129
Subject(s) - medicine , breast cancer , biomarker , dysplasia , atypical hyperplasia , breast disease , estrogen receptor , aneuploidy , pathology , cancer , hyperplasia , cytology , biopsy , risk factor , oncology , gastroenterology , gynecology , biology , biochemistry , gene , chromosome
Abstract Fine needle aspirates (FNA) from 106 high‐risk women and 25 low‐risk women were evaluated for overexpression of estrogen receptor (ER), epidermal growth factor receptor (EGFR), mutant p53, and HER‐2/ neu by immunocytochemistry, and for aneuploidy by image analysis. Aspirates were also classified cytologically as normal, apocrine metaplasia, epithelial hyperplasia (EH), or dysplasia. High‐risk women were those with a first‐degree relative with breast cancer (76%), precancerous breast disease (26%), prior cancer of the contralateral breast (9%), or multiple abnormalities (11%). Low‐risk women had none of the above risk factors, nor a prior breast biopsy or clinical evidence of fibrocystic disease. The median 10‐year Gail risk for the high‐risk group was 4%, compared to 0.7% for the low‐risk group. There were significant differences (p < 0.01) between high‐ and low‐risk women in the prevalences of hyperplasia (55% versus 12%), dysplasia (19% versus 0%), aneuploidy (32% versus 0%), overexpressed EGFR (32% versus 4%), and overexpressed p53 (29% versus 4%). The prevalence of multiple biomarker abnormalities was also greater in high‐risk than in low‐risk women (28% versus 0%; p < 0.01). Four percent (4%) of FNAs from high‐risk women with normal cytology, 29% of aspirates with hyperplastic cytology, and 60% of those with dysplasia were associated with two or more biomarker abnormalities. The differences in the prevalence of multiple biomarker abnormalities among various cytologic categories were statistically significant (p = 0.02, normal versus EH; p = 0.02, EH versus dysplasia; p < 0.01, normal versus dysplasia). Further study of these tissue biomarkers as potential intermediate‐term (5–10 year) predictors of breast cancer development is warranted.